Applied Proteomics said this week that it has closed a $28 million Series C financing round.

The company plans to use the funds to support development and commercialization of its first proteomic diagnostic, a mass spectrometry-based blood test to aid in the early detection of colorectal cancer, as well as to launch discovery efforts in several new indications, API President and CEO Peter Klemm told ProteoMonitor.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.